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Objectives The aim of this study was to evaluate the cost-effectiveness of transcatheter aortic valve replacement (TAVR) com-
pared with surgical aortic valve replacement (AVR) for patients with severe aortic stenosis and high surgical risk.
Background TAVR is an alternative to AVR for patients with severe aortic stenosis and high surgical risk.
Methods We performed a formal economic analysis based on cost, quality of life, and survival data collected in the
PARTNER A (Placement of Aortic Transcatheter Valves) trial in which patients with severe aortic stenosis and high
surgical risk were randomized to TAVR or AVR. Cumulative 12-month costs (assessed from a U.S. societal perspec-
tive) and quality-adjusted life-years (QALYs) were compared separately for the transfemoral (TF) and transapical (TA)
cohorts.
Results Although 12-month costs and QALYs were similar for TAVR and AVR in the overall population, there were impor-
tant differences when results were stratified by access site. In the TF cohort, total 12-month costs were slightly
lower with TAVR and QALYs were slightly higher such that TF-TAVR was economically dominant compared with
AVR in the base case and economically attractive (incremental cost-effectiveness ratio $50,000/QALY) in
70.9% of bootstrap replicates. In the TA cohort, 12-month costs remained substantially higher with TAVR,
whereas QALYs tended to be lower such that TA-TAVR was economically dominated by AVR in the base case and
economically attractive in only 7.1% of replicates.
Conclusions In the PARTNER trial, TAVR was an economically attractive strategy compared with AVR for patients suitable for
TF access. Future studies are necessary to determine whether improved experience and outcomes with TA-TAVR
can improve its cost-effectiveness relative to AVR. (THE PARTNER TRIAL: Placement of AoRTic TraNscathetER
Valve Trial; NCT00530894) (J Am Coll Cardiol 2012;60:2683–92) © 2012 by the American College of Cardiol-
ogy Foundation
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Cost-Effectiveness of TAVR in High-Risk Patients December 25, 2012:2683–92Transcatheter aortic valve replace-
ment (TAVR) was recently devel-
oped as an effective treatment for
severe aortic stenosis (AS) that is less
invasive than traditional surgical aor-
tic valve replacement (AVR). In the
PARTNER (Placement of Aortic
Transcatheter Valves) B trial,
TAVR was shown to lead to sub-
stantial gains in both survival and
quality of life (QOL) compared
with standard nonsurgical therapy in
patients with severe AS who were
unsuitable for AVR based on ana-
tomic factors or surgical risk (1,2).
Although the short-term costs of
TAVR were high in that study,
formal economic evaluation demonstrated that the benefits of
TAVR in such inoperable patients were achieved at an acceptable
incremental cost to society, at least in the context of the U.S.
health system (3).
In patients with severe, symptomatic AS who are at high
but not prohibitive surgical risk, the PARTNER A trial
recently demonstrated that TAVR using the Edwards
SAPIEN valve results in similar 1- and 2-year survival
compared with standard surgical AVR (4,5). Although rates
of periprocedural complications differed between the treat-
ments, at 2 years, the overall rates of major adverse events,
including stroke, were similar as well. On the other hand,
TAVR did result in significant early benefits in terms of
health-related QOL, but these benefits were no longer
present 6 to 12 months post-procedure and were observed
only when TAVR was performed via the transfemoral (TF)
but not the transapical (TA) route (6).
Given the similar 1- and 2-year clinical outcomes of
TAVR and AVR in the PARTNER A trial, secondary
considerations such as cost may affect the adoption of
TAVR. For high-risk surgical candidates, however, a direct
comparison of the costs and cost-effectiveness of TAVR and
AVR has not yet been reported. To address these questions,
we performed a prospective health economic study in
conjunction with the PARTNER A trial.
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Abbreviations
and Acronyms
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EQ-5D  EuroQol
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effectiveness ratio
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intention-to-treat
QOL  quality of life
TA  transapical
TAVR  transcatheter
aortic valve replacement
TF  transfemoralp
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Study design and patient population. As previously re-
ported, Cohort A of the PARTNER trial enrolled 699 patients
with severe, symptomatic AS, defined as an aortic valve area
0.8 cm2 with either a mean valve gradient40 mm Hg or a
peak jet velocity 4.0 m/s and New York Heart Association
functional class II or higher (4). All patients were required to
ave a predicted risk of operative mortality rate of 15% or a
ociety of Thoracic Surgery risk score of 10.
After enrollment in the trial, but before randomization,
atients were evaluated for anatomic suitability for TAVR
ia the TF approach based on imaging of the aorta and
liofemoral arterial system. Those patients found to be
uitable for TF access were then randomized to TF-TAVR
ersus AVR (TF cohort, n  492), whereas those patients
ho were not suitable for a TF approach (due to angio-
raphic findings precluding safe placement of a 22- or 24-F
ntroducer sheath such as severe obstructive calcification,
ortuosity, or vessel diameter 7 mm) were randomized to
A-TAVR versus AVR (TA cohort, n  207).
nalytic overview. Our economic analysis was performed
rom the perspective of the U.S. health care system (i.e., a
odified societal perspective). All costs are reported in 2010
.S. dollars. We performed our primary analyses on a
odified intention-to-treat (mITT) population, which was
efined by excluding 42 subjects from the intention-to-treat
opulation who received neither study treatment (mainly
ue to refusal, early withdrawal, or clinical deterioration [4])
nd 10 additional subjects who did not have complete
ollow-up information through either death or 12 months
see Figure 1 for details). Additionally, for the purpose of
escribing index admission resource use and costs among
nly those patients who actually underwent a true attempt at
alve implantation, we defined a secondary “treated as
andomized” population, which excluded the 42 patients
ho did not receive either treatment and a different set of 10
atients whose procedures were abandoned at preliminary
tages due to transesophageal echocardiographic findings or
ailed vascular access (9 TAVR, 1 AVR). All analyses followed
he principle of intention to treat by grouping patients accord-
ng to their randomized treatment assignment.
Although the primary clinical analysis of the PARTNER
trial pooled all patients treated in either the TA or TF
ohort, for the economic analysis, we made the a priori
ecision to stratify the analysis according to access site (TF
r TA) for several reasons. First, study randomization was
tratified by access site, and the TF cohort was indepen-
ently powered to demonstrate the noninferiority of TAVR
ompared with AVR for the trial’s primary endpoint of
2-month mortality (4). In addition, although TAVR
rocedures done via both TF and TA routes functionally
eplace the aortic valve in a similar manner, TF and TA
rocedures have fundamental differences in terms of ana-
omic site, risk, and, potentially, recovery. Finally, in a
revious analysis from this trial (6), we found a significant
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and access site (TF or TA) on QOL outcomes. For all of
these reasons, we thought that independent health eco-
nomic analyses of TF-TAVR and TA-TAVR, each com-
pared with their separate AVR control groups, would be
most relevant and informative.
Index procedure and admission costs. Costs were deter-
mined using a combination of hospital billing data and
resource-based accounting methods, as described previously
(7,8). For the initial TAVR and AVR procedures, study
centers recorded procedure duration and counts of major
items used, such as valve prostheses, support wires, guiding
catheters, valvuloplasty balloons, temporary pacing cathe-
ters, and vascular closure devices (3). Procedural costs were
calculated by multiplying item counts by their respective
unit prices, determined by the average acquisition costs at a
sample of U.S. hospitals. An acquisition cost of $30,000 was
used for the Edwards SAPIEN valve system, and a cost of
$5,277 was used for a standard bioprosthetic aortic valve.
Ancillary costs for the catheterization laboratory or operat-
ing room included overhead and depreciation, nonphysician
personnel, and general supplies required for each procedure
and were estimated based on a survey of study hospitals and
adjusted for observed procedure duration. We assumed that
TF-TAVR procedures would be performed in a catheter-
ization laboratory setting, whereas TA-TAVR procedures
Figure 1 Analysis Populations
Of the 699 patients randomized in PARTNER, 42 were not treated with either
procedure and were excluded from this analysis. After excluding an additional
10 patients with incomplete 12-month clinical or cost data, mainly due to with-
drawal after the index admission, the primary analytic population consisted of
647 patients (blue boxes) who were analyzed according to the intention-to-treat
principle. This population is referred to as the modified intention-to-treat popu-
lation for the purpose of this economic study. AVR  aortic valve replacement;
TAVR  transcatheter aortic valve replacement.and AVR procedures would be performed in an operatingroom setting, based on a survey of PARTNER trial sites at
the completion of the study.
Costs of the remainder of each index admission were
calculated from hospital bills, which were available for 525
subjects in the primary mITT population (80%), by multi-
plying all nonprocedural charges by cost center–specific
cost-to-charge ratios from each hospital’s Medicare cost
report (9). For admissions without available billing data
(n  132), the remainder of costs were estimated using
linear regression models derived from the subjects with
complete billing data. Covariates in these models, which
were derived separately for the TAVR and AVR groups
(R2  0.83 and 0.78, respectively), included intensive care
unit and non–intensive care unit length of stay, in-hospital
bleeding, and in-hospital death.
Follow-up hospitalization costs. Information on follow-up
hospital admissions for any cause was collected by the study
sites at scheduled follow-up visits (1, 6, and 12 months) and
on learning of adverse events. Costs for subsequent hospital
admissions were calculated from billing data using hospital
and cost center–specific cost-to-charge ratios when bills
were available (65% of admissions). When bills were not
available (mainly because of admission to non-U.S. or
nonstudy hospitals), diagnosis, procedure, and adverse event
information from the study database were used to assign
each admission to a unique Medicare Severity-Adjusted
Diagnosis-Related Group. Mean reimbursements for each
respective Medicare Severity-Adjusted Diagnosis-Related
Group, based on 2008 Medicare Provider Analysis and
Review data (10), were used as the proxy for admission costs
in these cases.
Physician fees. We assumed that physician fees for the
index AVR and TAVR procedures would be identical and
assigned these costs using current reimbursement rates for
surgical AVR from the Medicare fee schedule including
both a primary operator and a surgical assistant. In addition,
for the index procedure, we included physician fees for
cardiac anesthesia (based on measured procedure duration)
and intraoperative transesophageal echocardiography. Phy-
sician fees for the initial consultation and daily care during
the remainder of the initial hospital stay were also derived
from the Medicare fee schedule. For follow-up hospitaliza-
tions, we estimated total physician fees based on the
diagnosis-related group for each admission, as described
previously (11). In sensitivity analyses, we assigned physi-
cian costs to subsequent hospitalizations based on a fixed
percentage of hospital costs for each admission (ranging
from 10% to 30%).
Other costs. At each follow-up visit through 12 months,
enrolling sites collected data on rehabilitation facility stays,
nursing home stays, and outpatient resource use (emergency
department visits, physician office visits, outpatient cardiac
testing). We estimated costs for services using national
average per-diem rates for residential care and Medicare
reimbursement rates for outpatient care based on the Medi-
care fee schedule. Outpatient medication costs were as-
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Cost-Effectiveness of TAVR in High-Risk Patients December 25, 2012:2683–92sumed to be similar and therefore excluded from our
analysis.
Quality-adjusted life expectancy. Patients completed the
EuroQol (EQ-5D) health status questionnaire at baseline
and 1, 6, and 12 months. EQ-5D responses were converted
to utility weights using a published algorithm derived from
a U.S. population reference group (12). Quality-adjusted
life-years (QALYs) were calculated for each patient by
multiplying observed survival duration by the time-
weighted average of his or her utility values, with the
midpoint between assessments used as the transition be-
tween health states (13). Missing utility values were esti-
mated by multiple imputation techniques, taking into ac-
count baseline patient characteristics, clinical events,
number of hospitalizations, and previous utility values.
Statistical methods. Categorical data are reported as fre-
quencies, and continuous data are reported as mean  SD.
Discrete variables were compared using the Fisher exact
test. Normally distributed continuous variables were com-
pared using the 2-sample t test, and non-normally distrib-
uted data were compared by the Wilcoxon rank sum test.
Cost data are reported as both mean and median values and
compared using t tests, which are appropriate given our
focus on comparing mean costs between groups (rather than
the underlying distributions) (14).
We evaluated the cost-effectiveness of TAVR relative to
AVR, expressed as the incremental cost per QALY gained
over the initial 12-month follow-up period, with separate
analyses for the TF and TA cohorts. This analytic time
horizon is comparable to a lifetime analysis under the
assumption that all major clinical and economic outcomes
between the TAVR and AVR groups would be equivalent
after 1 year. On the basis of the empirical data from the
PARTNER A trial, we believe that this is a reasonable
assumption because there were no differences in either
survival or functional status between TAVR and AVR at 1
or 2 years (4–6), and preliminary data have shown no
divergence in the survival curves to 3 years (15).
Baseline Characteristics (Modified ITT Population)Table 1 Baseline Characteristics (Modified ITT Population)
TF Cohort
TAVR
(n  239)
AVR
(n  217)
Age, yrs 83.9 6.8 84.8 6.5
Male 60.7 56.2
STS risk score 11.8 3.2 11.6 3.3
Previous MI 26.8 25.8
Previous CABG 39.3 40.1
Cerebrovascular disease 23.8 24.0
Peripheral artery disease 34.6 35.0
COPD (oxygen dependent) 8.8 7.4
LV ejection fraction 52.2 14.1 53.6 13.1
Frailty 16.1 19.0
Values are mean  SD or %.
AVR  aortic valve replacement; CABG  coronary artery bypass graft; COPD  chronic obstructive p
Surgeons; TA  transapical; TAVR  transcatheter aortic valve replacement; TF  transfemoral.Incremental cost-effectiveness ratios (ICERs) were calcu-
lated as the difference in mean cumulative 12-month costs
divided by the difference in mean 12-month quality-
adjusted life expectancy. Bootstrap resampling (16,17) was
used to assess the joint distribution of lifetime cost and
survival differences.
In the TA cohort, baseline EQ-5D utility scores were
slightly lower in the TAVR group compared with the AVR
group (0.67 vs. 0.72, p 0.07) (6), and our primary analysis
was based on the observed data for the mITT population.
To account for this unexpected imbalance in baseline utility
scores, we performed a secondary analysis for the TA cohort
in which all utility scores (both baseline and follow-up) were
increased in TAVR patients and decreased in AVR patients
by half of the between-group baseline difference, such that
baseline utility scores between groups were equal (18).
Results
Of the 699 patients enrolled in Cohort A of the PARTNER
trial, 657 underwent an attempted TAVR or AVR proce-
dure (Fig. 1). Among this “treated” population, 10 subjects
had incomplete clinical or health economic data within the
12 months after randomization and were excluded from our
primary analysis. The remaining 647 subjects constituted
our primary mITT analysis population.
The baseline characteristics of the primary mITT popu-
lation were well balanced in both the TF and TA cohorts
(Table 1). Patients enrolled in the TA cohort (who were, by
definition, unsuitable for the TF approach) more frequently
had a history of peripheral arterial and cerebrovascular
disease than patients in the TF cohort. No differences were
observed in the baseline characteristics of the 52 subjects
excluded from the mITT population, compared with those
included (Online Table).
Index procedural and admission resource use and
costs. Major items of resource use and calculated costs for
the index procedures and hospital stays for the “treated as
TA Cohort
p Value
TAVR
(n  101)
AVR
(n  90) p Value
0.14 83.1 6.9 83.4 5.5 0.76
0.34 50.5 58.9 0.25
0.42 11.8 3.7 12.0 3.5 0.69
0.81 26.7 36.7 0.14
0.87 50.5 55.6 0.48
0.98 36.6 27.8 0.19
0.92 62.4 62.5 0.99
0.58 10.9 7.8 0.46
0.25 53.4 12.3 53.5 10.9 0.98
0.48 15.8 18.0 0.70ulmonary disease; LV  left ventricular; MI  myocardial infarction; STS  Society of Thoracic
s in Tab
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cohort) and Table 3 (for the TA cohort). In the TF cohort,
TAVR procedures were 90 min shorter than AVR pro-
cedures, but given the higher acquisition cost of the trans-
catheter valve system, TAVR procedural costs were signif-
icantly higher ($36,652  $4,703 vs. $14,475  $2,612).
Mean length of stay for TF-TAVR admissions was6 days
shorter than for AVR admissions including a mean differ-
ence of 2 intensive care unit days. This reduced length of
stay was associated with substantially lower nonprocedural
hospital costs after TF-TAVR compared with AVR, such
that overall admission costs were not significantly different
between groups ($73,219 vs. $74,067, mean difference,
$849; 95% CI: $8,977 to $7,014).
In the TA cohort, index procedure duration was shorter
for TAVR than for AVR, and total procedure costs were
higher ($40,368  $12,651 vs. $15,076  $2,665). Al-
though mean overall (14.7 10.1 days vs. 16.1 12.5 days)
and post-procedure (12.4  9.9 vs. 14.4  12.2) lengths of
stay were 1 to 2 days shorter with TA-TAVR compared
with AVR, the resulting cost savings were insufficient to
Index Admission Resource Use and Costs, Transfemoral Cohort (TrTable 2 Index Admission Resource Use and Costs, Transfemor
Resource Category
TF-TAVR
(n  234)
Procedure duration, min 244 78 [231]
Total hospital LOS, days 10.2 11.1 [7] 1
ICU 3.3 6.0 [2]
Non-ICU 6.9 7.8 [4] 1
Post-procedure 7.4 10.0 [5] 1
Major vascular complication 13.2%
Major bleeding 9.4%
Costs, $
Procedural 36,652 4,703 [35,609] 14,
Nonprocedural 31,705 38,308 [20,745] 53,
Physician fees 4,861 1,549 [4,433] 5,
Total admission costs 73,219 40,596 [61,162] 74,
Values are mean  SD [median] or %.
CI  confidence interval; ICU  intensive care unit; LOS  length of stay; other abbreviations a
Index Admission Resource Use and Costs, Transapical Cohort (TreTable 3 Index Admission Resource Use and Costs, Transapical
Resource Category
TA-TAVR
(n  101)
Procedure duration, min 224 76 [210]
Total hospital LOS, days 14.7 10.1 [10]
ICU 6.6 8.9 [3]
Non-ICU 8.1 7.0 [6]
Post-procedure 12.4 9.9 [9]
Major vascular complication 4.0%
Major bleeding 5.9%
Costs, $
Procedural costs 40,368 12,651 [37,853] 1
Nonprocedural costs 44,909 34,603 [30,091] 5
Physician fees 5,642.22 1,890.62 [4,929]
Total admission costs 90,919 39,397 [74,721] 7Values are mean  SD [median] or %.
Abbreviations as in Tables 1 and 2.offset the higher procedural costs. Consequently, total
admission costs remained higher with TA-TAVR com-
pared with AVR ($90,919 vs. $79,024; mean difference,
$11,896; 95% CI: $1,012 to $24,304).
Follow-up resource use and costs. Resource use and costs
from hospital discharge through 12 months for the TF and TA
cohorts (mITT population) are summarized in Tables 4 and 5,
respectively. In the TF cohort, there were no differences
between TAVR and AVR patients in terms of repeat
hospital admissions, follow-up hospital days, or measures of
major outpatient resource use, although TAVR patients
tended to require slightly less rehabilitative care and slightly
more skilled nursing care. Follow-up costs through 12
months were similar for the TF-TAVR and AVR groups
(mean difference, $1,247; 95% CI: $12,426 to $14,074).
Likewise, in the TA cohort, there were no significant
differences in major categories of resource use between the
TAVR and AVR groups, although there was a tendency
toward fewer rehabilitative care days and more skilled
nursing days in the TA-TAVR group. Total follow-up costs
through 12 months were slightly, but not significantly,
as Randomized Population)hort (Treated as Randomized Population)
AVR
 221) Difference (95% CI) p Value
102 [315] 87 (69 to104) 0.001
13.9 [12] 6.2 (3.8 to8.2) 0.001
6.7 [3] 2.3 (0.9 to3.3) 0.001
10.2 [8] 4.0 (2.2 to5.5) 0.001
12.1 [10] 6.1 (3.7 to8.0) 0.001
3.2% 10.1% (5.1 to 15.1) 0.001
22.6% 13.2% (6.6 to19.9) 0.001
2,612 [14,081] 22,177 (21,496 to 22,884) 0.001
45,572 [40,439] 22,129 (29,880 to14,469) 0.001
1,810 [5,179] 896 (1209 to594) 0.001
47,422 [59,687] 849 (8,977 to 7,014) 0.84
le 1.
as Randomized Population)ort (Treated as Randomized Population)
AVR
(n  91) Difference (95% CI) p Value
 104 [335] 130 (104 to155) 0.001
 12.5 [12] 1.4 (1.7 to4.7) 0.39
 11.0 [4] 1.4 (1.3 to4.4) 0.33
 6.2 [7] 0.0 (1.9 to1.8) 1.0
 12.2 [9] 2.0 (1.1 to5.3) 0.22
4.4% 0.4% (6.2% to5.3%) 1.0
20.9% 14.9% (5.5% to24.3%) 0.002
 2,665 [14,592] 25,292 (23,091 to 28,145) 0.001
 44,815 [39,103] 12,918 (24,763 to1,805) 0.03
 2,418 [5,302] 479 (1,145 to 103) 0.13
 47,343 [61,395] 11,896 (1,013 to 24,304) 0.06eatedal Co
(n
330
6.4
5.6
0.8
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758
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ence, $1,102; 95% CI: $10,590 to $8,661).
Over the full study period, cumulative 12-month costs in
he mITT population were marginally lower for TF-TAVR
ompared with AVR (mean difference, $1,250; 95% CI:
$18,132 to $13,867). In the TA cohort, cumulative
2-month costs were higher for TAVR compared with
VR (mean difference, $9,906; 95% CI: $5,263 to
24,814). Pooled results for the full mITT population
emonstrated slightly higher costs with TAVR than
VR ($100,504 vs. $98,434; mean difference, $2,070;
5% CI: $9,960 to $13,499).
ife-years and QALYs. Life expectancy and quality-
djusted life expectancy for the mITT population are
ummarized in Table 6. As previously described, for the TF
ohort, both early survival and QOL tended to favor the
AVR group (4,6), resulting in small but significant differ-
nces in life expectancy and quality-adjusted life expectancy.
n the TA cohort, no difference in mortality was observed at
Cumulative 1-Year Resource Use and Costs, Transfemoral Cohort (Table 4 Cumulative 1-Year Resource Use and Costs, Transfem
TF-TAVR
(n  239)
Follow-up hospitalizations 0.9 1.3
Cardiovascular 0.3 0.7
Noncardiovascular 0.6 1.0
Rehabilitation days 2.3 9.0
Skilled nursing days 11.2 45.9
Costs, $
Index admission* 71,955 37,747 [61,297] 74,4
Follow-up hospitalizations 18,122 58,142 15,6
Rehabilitation 2,316 9,213 4,6
Skilled nursing 3,223 13,182 2,3
Other outpatient services 1,126 2,584 8
Total follow-up costs 24,787 64,348 [5,580] 23,5
Total 12-month costs 96,743 76,185 [71,975] 97,9
Values mean  SD or mean  SD [median]. *Note that index admission costs for the mITT popu
mITT  modified intention-to-treat; other abbreviations as in Table 2.
Cumulative 1-Year Resource Use and Costs, Transapical Cohort (mTable 5 Cumulative 1-Year Resource Use and Costs, Transapic
TA-TAVR
(n  101)
Follow-up hospitalizations 0.7 1.1
Cardiovascular 0.3 0.6
Noncardiovascular 0.4 0.8
Rehabilitation days 3.2 16.9
Skilled nursing days 10.4 36.3
Costs, $
Index admission* 90,548 39,909 [74,721] 79
Follow-up hospitalizations 11,733 31,924 [0] 11
Rehabilitation 3,254 17,303 [0] 4
Skilled nursing 2,995 10,415 [0] 2
Other outpatient services 874 1,468 [0] 1
Total follow-up costs 18,856 41,604 [3,731] 19
Total 12-month costs 109,405 56,874 [92,819] 99Values mean  SD or mean  SD [median]. *Note that index admission costs for the mITT population d
Abbreviations as in Tables 3 and 4.ny time point, and early QOL tended to be better in the
VR group (4,6). Thus, for the TA cohort, life-years were
imilar for the TAVR and AVR groups, whereas quality-
djusted life expectancy tended to be less with TAVR.
hen results were pooled across both access sites, there
ere nonsignificant trends toward greater life expectancy
nd quality-adjusted life expectancy with TAVR compared
ith AVR.
ost-effectiveness analysis. The results of the trial-based
ost-effectiveness analysis are summarized in Table 7. For
he overall mITT population, TAVR resulted in slightly
igher 12-month costs and a small gain in QALYs with a
esulting ICER of $76,877/QALY gained. This result was
ighly uncertain, however, because TAVR was found to be
ominant in 34.5% of bootstrap replicates but either dom-
nated or economically unattractive (ICER $100,000/
ALY) in 48.5%.
The cost-effectiveness results differed substantially ac-
ording to access site. Among patients suitable for a TF
Population)ohort (mITT Population)
AVR
 217) Difference (TAVR-AVR) (95% CI) p Value
1.0 0.3 (0.1 to 0.5) 0.02
0.6 0.0 (0.1 to 0.2) 0.51
0.7 0.2 (0.1 to 0.4) 0.01
21.9 2.3 (5.3 to 0.7) 0.14
38.3 2.9 (5.0 to 10.7) 0.47
47,725 [60,159] 2,496 (10,312 to 5,428) 0.53
77,412 2,477 (11,156 to 14,382) 0.70
22,492 2,350 (5,948 to 200) 0.14
11,002 827 (1452 to 3,164) 0.47
1,510 293 (47 to 701) 0.14
82,003 [5,535] 1247 (12,426 to 14,074) 0.86
94,873 [74,361] 1,250 (18,132 to 13,867) 0.88
iffer slightly from the treated as randomized population as shown in Table 2.
opulation)hort (mITT Population)
AVR
(n  90) Difference (TAVR-AVR) (95% CI) p Value
1.1 0.1 (0.4 to 0.2) 0.68
0.7 0.0 (0.2 to 0.2) 0.81
0.9 0.0 (0.3 to 0.2) 0.72
17.5 1.6 (6.5 to 3.3) 0.38
38.5 2.8 (7.8 to 13.5) 0.60
47,429 [61,784] 11,008 (2,053 to 22,485) 0.08
20,414 [0] 41.37 (6,675 to 8,090) 0.99
17,951 [0] 1,676 (6,734 to 3,108) 0.51
11,053 [0] 814 (2,296 to 3,665) 0.60
1,961 [0] 282 (771 to 199) 0.27
29,618 [8,666] 1,102 (10,590 to 8,661) 0.84
54,541 [86,747] 9,906 (5,263 to 24,814) 0.22mITToral C
(n
0.6
0.2
0.4
4.5
8.4
52
45
66
97
33
40
92ITT Pal Co
0.8
0.3
0.5
4.8
7.6
,540
,692
,930
,181
,156
,959
,499iffer slightly from the treated as randomized population as shown in Table 2.
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patient and a modest gain in QALYs compared with
AVR. Bootstrap simulation demonstrated that TF-
TAVR was economically dominant compared with AVR
in 55.7% of replicates and economically attractive at an
ICER of $50,000/QALY gained in 70.9% (Fig. 2A). On
the other hand, among patients who were unsuitable for
TF access, TA-TAVR resulted in higher 12-month costs
and lower quality-adjusted life expectancy than AVR in
our primary analysis and was economically dominated by
AVR in 86.6% of bootstrap replicates (Fig. 2B). At an
ICER threshold of $50,000/QALY, TA-TAVR was
economically attractive relative to AVR in just 7.1% of
replicates.
Threshold analysis demonstrated that the ICER for
TF-TAVR would remain $50,000/QALY as long as the
ifference in acquisition cost between the TAVR device and
standard bioprosthetic valve remained $29,390. On the
ther hand, assuming no change in other clinical or eco-
omic outcomes, TA-TAVR would be economically attrac-
ive at this ICER threshold only if the difference in valve
cquisition costs was $11,324.
ensitivity analyses. When the analysis was expanded to
nclude the full “treated” population (N  657), TAVR
arginally increased costs in the TF cohort by $396/patient,
nd TAVR was economically dominant in 46.0% of boot-
trap replicates and economically attractive at an ICER of
50,000/QALY in 61.9%. For the TA cohort, the incre-
ental cost associated with TAVR increased slightly to
10,227/patient, and TAVR remained economically domi-
ated by AVR in 87.7% of replicates. Finally, when the
nalysis for the TA cohort was repeated after adjusting for
Life-Years and QALYs Over the12-Month Follow-Up Period (mITT Population)Table 6 Life-Years and QALYs Over the12-Month Follow-Up Period (mITT Population)
TAVR AVR TAVR-AVR 95% CI*
All patients
Life-years 0.858 0.817 0.041 0.010 to 0.088
QALYs 0.633 0.606 0.027 0.018 to 0.071
Transfemoral cohort
Life-years 0.878 0.813 0.065 0.011 to 0.125
QALYs 0.659 0.591 0.068 0.017 to 0.123
Transapical cohort
Life-years 0.811 0.826 0.015 0.103 to 0.080
QALYs 0.570 0.641 0.070 0.151 to 0.012
*95% confidence intervals calculated from bootstrap resampling.
QALYs  quality-adjusted life-years; other abbreviations as in Table 3.
Primary Cost-Effectiveness Results (mITT Population)Table 7 Primary Cost-Effectiveness Results (mITT Population)
Population Cost, $ QALYs ICER ($/QALY)
Overall 2,070 0.027 76,877
TF cohort 1,250 0.068 TAVR dominant
TA cohort 9,906 0.07 TAVR dominatedResults based on mITT population; probabilities derived from bootstrap simulation.
ICER  incremental cost-effectiveness ratio; other abbreviations as in Tables 1, 4, and 6.the baseline imbalance in EQ-5D utility scores, the differ-
ence in quality-adjusted life expectancy between TA-TAVR
and AVR was smaller (mean difference, 0.036 QALYs,
95% CI: 0.117 to 0.046). Nonetheless, TA-TAVR re-
Probability TAVR
Dominant, %
Probability TAVR
Dominated, %
Probability ICER
<$50,000/QALY, %
34.5 10.5 43.8
55.7 0.5 70.9
1.1 86.6 7.1
Figure 2 Cost-Effectiveness Results
Mean incremental 12-month costs and QALYs (TAVR–AVR) are plotted on the
cost-effectiveness plane for the transfemoral (TF) (A) and transapical (TA) (B)
cohorts. The solid circles represent base-case estimates, the surrounding
open circles represent individual results for 1,000 replications of the study
using bootstrap resampling, and the dashed lines represent a willingness to
pay a threshold of $50,000/QALY gained. For the TF cohort, the base-case
results are a gain of 0.068 QALYs and cost savings of $1,250 per patient. For
the TA cohort, the base-case results are a “loss” of 0.070 QALYs and a net
increase in costs of $9,906. QALYs  quality-adjusted life-years; other abbrevi-
ations as in Figure 1.
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bootstrap replications. Using a fixed ratio of physician costs
to hospitalization costs (ranging from 10% to 30%) or
estimating the costs of all readmissions based on diagnosis-
related groups had only a slight effect on our findings
(results not shown).
Discussion
Although the PARTNER trial previously examined the
cost-effectiveness of TAVR compared with standard ther-
apy for patients who are not candidates for surgical valve
replacement (3), this study represents the first attempt to
directly evaluate the incremental cost-effectiveness of
TAVR relative to AVR among patients who are acceptable
candidates for high-risk surgical AVR. In this prospectively
designed analysis of 12-month economic outcomes in the
PARTNER A trial, we found that TAVR and AVR
resulted in 12-month costs and QALYs that were suffi-
ciently similar that neither therapy would be clearly pre-
ferred over the other on health economic grounds.
Economic outcomes differed substantially, however,
when the analysis was stratified by TAVR access site.
Among the 70% of trial patients who were eligible for a
F approach, TAVR provided a modest benefit in quality-
djusted life expectancy and slightly reduced costs compared
ith AVR. As a result, TF-TAVR was found to be
conomically attractive by generally accepted standards and
ossibly an economically dominant strategy compared with
VR in these patients. In contrast, for the minority of
atients who were suitable for TAVR only via the TA
pproach, we observed higher 12-month costs and a trend
oward reduced quality-adjusted life expectancy compared
ith AVR in the PARTNER A population.
These differences in cost-effectiveness are explained by
ifferences in both hospital resource use and short-term
linical outcomes of TAVR according to access site. Proce-
ural costs for both TF-TAVR and TA-TAVR were
ubstantially greater than those for surgical AVR, driven
lmost entirely by the higher valve acquisition costs. In the
F cohort, however, TAVR resulted in substantial reduc-
ions in length of stay compared with AVR with associated
ost savings sufficient to fully offset the higher procedural
osts. In addition, formal QOL and utility assessment
emonstrated significant early benefits with TF-TAVR. As
result, TF-TAVR compared favorably with AVR on
oth clinical and economic grounds. In contrast, among
atients who were ineligible for a TF approach, TA-
AVR resulted in only a 1- to 2-day reduction in length
f hospital stay, which was insufficient to offset the higher
rocedural costs, and early QOL was not improved
ompared with AVR.
We are aware of only 1 previously published study (19)
ssessing the cost-effectiveness of TAVR relative to AVR in
igh-risk surgical candidates in a U.S. practice setting. Gada
t al. (19) used a Markov model to estimate lifetime costsand QALYs for high-risk patients treated with TAVR,
AVR, or medical therapy, informed by a number of separate
TAVR and AVR registries. The investigators’ base-case
analysis used a “provider perspective” under which the costs
of index admissions for TAVR and AVR were assumed to
be equal. This model predicted a lifetime gain of 0.06
QALYs comparing TAVR with AVR, with slightly higher
lifetime costs, resulting in an ICER of $53,000/QALY
gained. Although the main results of the previous study are
consistent with our findings, the fundamentally different
methodologies make comparisons between the 2 studies
difficult. Although our study was limited to a 12-month
time horizon, our approach had several advantages includ-
ing a direct comparison of outcomes based on data from a
randomized clinical trial, use of empirically derived costs
from detailed analysis of hospital billing and resource use
data, and separately evaluating TF and TA access for
TAVR.
Although the economic outcomes of TAVR observed in
the TF cohort of the PARTNER trial are remarkably
positive for a relatively new technology in the early phase of
clinical use, the results in the TA cohort were less favorable.
Compared with AVR, TA-TAVR in the PARTNER trial
increased costs and did not appear to provide any measur-
able survival or QOL benefit. Potential reasons underlying
the lack of QOL benefit in the TA cohort have been
discussed previously (6) and could include postoperative
pain, early procedural complications, and limited experience
with the TA procedure and post-procedure management.
In addition, it is important to recognize the context in
which our study was conducted. As noted previously (4,6),
the TA cohort of PARTNER A was small and not
independently powered for major clinical endpoints such as
survival. More importantly, site- and operator-level experi-
ence with TA-TAVR procedures in the PARTNER trial
was very limited, with a median of 4 procedures per participating
center. It is thus evident that most PARTNER sites did not
perform enough TA-TAVR procedures to move beyond the
point of learning curve effects (20). It seems likely that
length of stay will shorten with greater experience, and it is
conceivable that clinical and QOL outcomes after TA-
TAVR may improve as well. Indeed, preliminary results from the
continued access phase of the PARTNER trial suggest that
substantial improvements in clinical outcomes of TA-TAVR
have already been achieved at the PARTNER centers (21,22).
Future studies are necessary to precisely quantify the nature
of these developments and their overall impact on the
cost-effectiveness of TA-TAVR.
One additional factor contributing to the higher incre-
mental costs associated with the TA approach is the
application of operating room overhead to the TA-TAVR
procedures as opposed to the somewhat lower cardiac
catheterization laboratory overhead, which was applied to
the TF procedures. This methodological decision was based
on a survey of PARTNER trial site practices at the end of
the study and is similar to current practice in Europe, where
2691JACC Vol. 60, No. 25, 2012 Reynolds et al.
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demonstrate that even had we applied catheterization lab
overhead rates to the TA-TAVR procedures, 12-month
costs would have remained $7,000 higher with TAVR
than with AVR. Thus, it is unlikely that changes in the
procedural setting alone would be sufficient to render
TA-TAVR an economically attractive procedure.
Although higher acquisition costs for the Edwards SAPIEN
valve compared with current bioprosthetic valves are a key
determinant of the cost-effectiveness of TAVR, sensitivity
analyses based on the PARTNER A results demonstrate
that substantial reductions in valve pricing (on the order of
$15,000 less than current levels) would be required for
TA-TAVR to be an economically attractive alternative to
surgical AVR if clinical and QOL outcomes of TA-TAVR
remain unchanged. For TA-TAVR to become a cost-
effective alternative to AVR at current valve acquisition
costs, it will be necessary to demonstrate substantial reduc-
tions in postoperative length of stay compared with the
PARTNER A results as well as early QOL outcomes that
are at least as good as (or better than) those achieved with
surgical AVR.
Study limitations. Our analysis should to be interpreted in
light of several important limitations. First, our study was
based a 12-month time horizon. This approach offered the
advantage of using only directly observed data, but does not
address any potential differences between TAVR and AVR
in long-term outcomes. Thus far, the durability of results
with TAVR appears good (23,24), and no differences in
survival or other major clinical outcomes between TAVR
and AVR have been observed in the PARTNER trial
population at 2 years (5), but truly long-term outcomes
comparing TAVR with AVR must await further study. In
addition, it is important to recognize that the PARTNER
A trial enrolled patients within a narrow range of surgical
risk. The results of this analysis thus cannot readily be
extrapolated to patient groups with lower surgical risk or to
patients with extensive comorbidities who would not gen-
erally be considered candidates for AVR. Our analysis was
based on U.S. patients, hospitals, and cost structures; results
in other health systems may differ. Finally, based on its
sample size, the PARTNER trial had limited statistical
power to identify small differences in outcomes, particularly
within subgroups. This fact, coupled with unavoidable
imprecision in some cost estimates, limits the certainty of
our findings.
Conclusions
Based on the PARTNER trial, for patients with severe AS
and high surgical risk, TAVR using the Edwards SAPIEN
valve appears to be an economically attractive strategy
compared with AVR, provided that patients are suitable for
a TF approach. On the other hand, results for TA-TAVR
compared with AVR were economically unfavorable in this
small, early U.S. experience. Additional study is needed toestablish whether clinical, QOL, and efficiency of care
outcomes improve sufficiently to render TA-TAVR an
economically attractive strategy as well.
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